Circulating the HLA-DR+ T Cell Ratio Is a Prognostic Factor for Recurrence of Patients with Hepatocellular Carcinoma after Curative Surgery

Table 3

Univariate and multivariate Cox regression analyses of risk factors associated with overall survival (OS) after curative surgery for hepatocellular carcinoma.

Variables	HR comparison	UV HR (95% CI)	UV value	MV HR (95% CI)	MV value
Gender	Male vs. female	1.895 (0.666–5.394)	0.231
Age	≥60 vs.<60 years	0.594 (0.282–1.251)	0.170
HbsAg positivity	Yes vs. no	2.223 (0.531–9.302)	0.274
Liver cirrhosis	Yes vs. no	1.836 (0.823–4.096)	0.138
AST/ALT	≥1 vs. <1	1.232 (0.588–2.580)	0.581
GGT level	≥45 U/L vs. <45 U/L	2.459 (1.239–4.880)	0.010	2.156 (1.020–4.558)	0.044
AFP positivity	Yes vs. no	2.241 (1.085–4.626)	0.029	1.534 (0.716–3.287)	0.271
CD3+ T cell ratio	≥77% vs. <77%	0.996 (0.407–2.435)	0.993
CD4+ T cell ratio	≥41.6% vs. <41.6%	0.412 (0.158–1.072)	0.069
CD8+ T cell ratio	≥29.6% vs. <29.6%	1.018 (0.500–2.074)	0.960
HLADR+ T cell ratio	≥5.8% vs.<5.8%	0.861 (0.434–1.707)	0.567
B cell ratio	≥18.2% vs. <18.2%	1.543 (0.733–3.249)	0.254
NK cell ratio	≥25.6% vs. <25.6%	1.326 (0.546–3.217)	0.533
Edmondson grade	III-IV vs. I-II	2.541 (1.269–5.089)	0.008	1.582 (0.727–3.441)	0.247
Largest tumor size	≥5 cm vs. <5 cm	2.885 (1.440–5.780)	0.003	2.346 (1.100–5.007)	0.027
Microvascular invasion	Yes vs. no	2.817 (1.409–5.634)	0.003	2.379 (1.085–5.215)	0.030
Capsular invasion	Yes vs. no	1.757 (0.878–3.515)	0.111
Prophylactic TACE after surgery	Yes vs. no	2.117 (1.068–4.194)	0.032	0.794 (0.345–1.831)	0.589

AFP: alpha-fetoprotein; AST: aspartate aminotransferase; ALT: alanine aminotransferase; GGT: gamma glutamyl transferase; TACE: transcatheter arterial chemoembolization.